Patents by Inventor Mark Abramovitz

Mark Abramovitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prognostic biomarkers to predict overall survival and metastatic disease in patients with triple negative breast cancer
    Patent number: 8642270
    Abstract: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer.
    Type: Grant
    Filed: February 8, 2010
    Date of Patent: February 4, 2014
    Assignee: VM Institute of Research
    Inventors: Brian Leyland-Jones, Mark Abramovitz
  • PROGNOSTIC BIOMARKERS TO PREDICT OVERALL SURVIVAL AND METASTATIC DISEASE IN PATIENTS WITH TRIPLE NEGATIVE BREAST CANCER
    Publication number: 20100210738
    Abstract: The present invention relates to a method for prognosing cancer in a subject with triple negative (TN) breast cancer, whose tumors lack expression of the estrogen receptor (ER), the progesterone receptor (PR) and normal (not amplified) levels of the human epidermal growth factor receptor 2 (HER2). Methods and biomarkers are disclosed that are useful for predicting the overall survival (OS) potential of cancer in a subject with triple negative breast cancer or for predicting metastatic disease in a subject with triple negative breast cancer. For example, the method comprises detecting in a sample from a subject one or more biomarkers selected from the group consisting of ANK3, CD24, EIF1, KLF6, KRAS, KRT1, MAP2K4, SDC4, SLC2A3, STK3, TFAP2C, and WRN. An increase or decrease in one or more biomarkers as compared to a standard is prognostic of OS of TN breast cancer.
    Type: Application
    Filed: February 8, 2010
    Publication date: August 19, 2010
    Applicant: VM INSTITUTE OF RESEARCH
    Inventors: Brian Leyland-Jones, Mark Abramovitz
  • BREAST CANCER GENE ARRAY
    Publication number: 20100087330
    Abstract: The present invention relates to a method for prognosing or classifying cancer subtypes in a subject with breast cancer. Methods and biomarkers are disclosed that are useful for prognosing or classifying ESR1, PGR and ERBB2 breast cancer subtypes.
    Type: Application
    Filed: January 25, 2008
    Publication date: April 8, 2010
    Inventors: Brian Leyland-Jones, Mark Abramovitz, Benjamin Gabriel Barwick
  • Methods of identifying modulators of a DP prostaglandin receptor
    Patent number: 6395499
    Abstract: A human prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the human prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 20, 2000
    Date of Patent: May 28, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Kathleen Metters, Yves Boie, Nicole Sawyer, Deborah M. Slipetz
  • Methods of identifying modulators of human IP prostaglandin receptor
    Patent number: 6365360
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: March 16, 1998
    Date of Patent: April 2, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • Methods of identifying modulators of a prostaglandin receptor
    Patent number: 6358694
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: March 19, 2002
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • DNA encoding prostaglandin receptor DP
    Patent number: 6214972
    Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: April 28, 1999
    Date of Patent: April 10, 2001
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
  • DNA encoding prostaglandin receptor DP
    Patent number: 5958723
    Abstract: A novel human DP prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: March 6, 1997
    Date of Patent: September 28, 1999
    Assignee: Merck Frosst Canada & Co.
    Inventors: Mark Abramovitz, Yves Boie, Kathleen Metters, Nicole Sawyer, Deborah M. Slipetz
  • DNA encoding prostaglandin receptor FP
    Patent number: 5869281
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: June 25, 1993
    Date of Patent: February 9, 1999
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Purified prostaglandin receptor FP
    Patent number: 5840847
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: November 21, 1997
    Date of Patent: November 24, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Richard Grygorczyk, Kathleen Metters, Truyen Nguyen, Thomas H. Rushmore, Deborah Slipetz
  • Prostaglandin receptor EP2
    Patent number: 5759789
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Mohammed Adam, Lison Bastien, Richard Grygorczyk, Kathleen Metters, Thomas H. Ruchmore, Nicole Sawyer
  • Human Prostaglandin receptor IP
    Patent number: 5728808
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: March 17, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Yves Bole, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • DNA encoding human prostaglandin receptor EP2
    Patent number: 5605814
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: February 25, 1997
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Mohammed Adam, Lison Bastien, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Nicole Sawyer
  • DNA encoding prostaglandin receptor IP
    Patent number: 5516652
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: October 6, 1993
    Date of Patent: May 14, 1996
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Yves Boie, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz